CHICAGO & WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). These analyses demonstrated that patients who responded to FOLOTYN had up to a 44% reduction in risk of death based on independent central review of response (P=.07), and up to a 56% reduction in risk of death based on investigator review of response (P=<.01), when compared with patients whose disease did not respond to FOLOTYN. These analyses also demonstrated that patients with stable disease who received FOLOTYN had a reduction in the risk of death when compared to patients with progressive disease. These data were presented during a poster session at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8, 2010 in Chicago, Illinois.
